Core Viewpoint - Galderma raised its full-year guidance after third-quarter sales exceeded expectations, leading to a 7% increase in share price [1][2] Group 1: Financial Performance - Third-quarter net sales reached $1.29 billion, surpassing the consensus estimate of $1.24 billion [1] - Full-year net sales are now expected to grow between 17% and 17.7% year-on-year at constant currency, an increase from the previous forecast of 12% to 14% [2] - The forecast for core EBITDA margin has been adjusted to between 23.1% and 23.6% at constant currency, up from about 23% previously [4] Group 2: Market Dynamics - The U.S. market saw a 17.5% increase in third-quarter net sales compared to the same quarter last year [3] - Despite facing a 39% import duty imposed by the U.S. government, Galderma's performance remains strong, prompting the company to increase employment in the U.S., Europe, and Asia [3] Group 3: Strategic Focus - Galderma is focusing on the U.S. market due to its strong growth potential and plans to invest over $650 million in U.S. manufacturing through 2030 [2] - The company is experiencing robust growth in its Nemluvio dermatology portfolio, contributing to its overall performance [2][3]